menu
    • menu

    Company profile for BridGene Biosciences

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BridGene Biosciences is a biotechnology company focusing on discovering and developing innovative small molecules that drug high value yet previously undruggable targets, providing new paths to treat diseases. Currently, about 90% of proteins associated with diseases cannot be targeted by traditional therapies due to the lack of a known addressable binding site. BridGene intends to change this by using its proprietary Chemo...
    BridGene Biosciences is a biotechnology company focusing on discovering and developing innovative small molecules that drug high value yet previously undruggable targets, providing new paths to treat diseases. Currently, about 90% of proteins associated with diseases cannot be targeted by traditional therapies due to the lack of a known addressable binding site. BridGene intends to change this by using its proprietary Chemoproteomics platform, IMTAC™ (Isobaric Mass Tagged Affinity Characterization).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BridGene BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    75 Nicholson Ln, San Jose, CA 95134
    Telephone
    Telephone
    1-408-498-8127
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bridgenebio.com/home
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BridGene Biosciences Raises $28 Million in Series B+ Financing
    BridGene Biosciences Raises $28 Million in Series B+ Financing

    27 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bridgene-biosciences-raises-28-million-in-series-b-financing-to-accelerate-clinical-development-of-bgc-515-and-platform-expansion-302585734.html

    PR NEWSWIRE
    27 Jan 2026
    Share Share
    Bridgene Biosciences Presents Three Posters At AACR-NCI-EORTC
    Bridgene Biosciences Presents Three Posters At AACR-NCI-EORTC

    23 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bridgene-biosciences-to-present-three-posters-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-302591266.html

    PR NEWSWIRE
    23 Oct 2025
    Share Share
    Takeda Pumps $770M Into BridGene Pact to Hit Targets
    Takeda Pumps $770M Into BridGene Pact to Hit Targets

    26 Feb 2025

    // BIOSPACE

    https://www.biospace.com/business/takeda-pumps-770m-into-another-bridgene-pact-to-hit-undruggable-targets

    BIOSPACE
    26 Feb 2025
    Share Share
    BridGene To Present Novel Covalent Inhibitors At 36th EORTC Symposium
    BridGene To Present Novel Covalent Inhibitors At 36th EORTC Symposium

    09 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bridgene-biosciences-to-present-three-novel-covalent-inhibitors-at-the-36th-eortc-nci-aacr-symposium-302270959.html

    PR NEWSWIRE
    09 Oct 2024
    Share Share
    BridGene And Galapagos Expand Collaboration On SMARCA2 PROTAC
    BridGene And Galapagos Expand Collaboration On SMARCA2 PROTAC

    01 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bridgene-biosciences-expands-strategic-collaboration-with-galapagos-to-develop-selective-oral-smarca2-protac-in-precision-oncology-302211935.html

    PR NEWSWIRE
    01 Aug 2024
    Share Share
    Galapagos Collaborates With BridGene Biosciences To Develop Cancer Treatments
    Galapagos Collaborates With BridGene Biosciences To Develop Cancer Treatments

    04 Jan 2024

    // YAHOO FINANCE

    https://finance.yahoo.com/news/european-drugmaker-galapagos-collaborates-biotech-230144995.html

    YAHOO FINANCE
    04 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search